Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 14,435 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $81.54, for a total transaction of $1,177,029.90. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Gilead Sciences, Inc. (NASDAQ:GILD) traded down $0.13 on Thursday, reaching $80.56. 2,330,000 shares of the company’s stock were exchanged, compared to its average volume of 10,150,000. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $89.54. The firm has a market cap of $105,210.00, a price-to-earnings ratio of 10.49, a PEG ratio of -1.85 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the previous year, the business earned $2.70 EPS. The business’s quarterly revenue was down 18.7% compared to the same quarter last year. equities analysts forecast that Gilead Sciences, Inc. will post 6.24 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 2.83%. The ex-dividend date is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 27.08%.
A number of research analysts have recently issued reports on the stock. Leerink Swann reiterated a “market perform” rating and issued a $80.00 target price (down previously from $83.00) on shares of Gilead Sciences in a research note on Thursday. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 target price for the company in a research note on Monday. Mizuho reiterated a “buy” rating and issued a $95.00 target price (up previously from $83.00) on shares of Gilead Sciences in a research note on Monday, February 12th. BMO Capital Markets lifted their target price on shares of Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a research note on Thursday, February 8th. Finally, Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average target price of $86.92.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wayne Hummer Investments L.L.C. boosted its position in shares of Gilead Sciences by 13.7% during the second quarter. Wayne Hummer Investments L.L.C. now owns 20,286 shares of the biopharmaceutical company’s stock worth $1,436,000 after purchasing an additional 2,450 shares in the last quarter. Boston Private Wealth LLC lifted its position in Gilead Sciences by 2.6% in the 2nd quarter. Boston Private Wealth LLC now owns 218,512 shares of the biopharmaceutical company’s stock valued at $15,466,000 after acquiring an additional 5,591 shares in the last quarter. Truepoint Inc. bought a new stake in Gilead Sciences in the 2nd quarter valued at $204,000. Tocqueville Asset Management L.P. lifted its position in Gilead Sciences by 2.2% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 35,133 shares of the biopharmaceutical company’s stock valued at $2,487,000 after acquiring an additional 757 shares in the last quarter. Finally, Van Cleef Asset Management Inc lifted its position in Gilead Sciences by 3.0% in the 2nd quarter. Van Cleef Asset Management Inc now owns 65,548 shares of the biopharmaceutical company’s stock valued at $4,639,000 after acquiring an additional 1,927 shares in the last quarter. 75.71% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) EVP Gregg H. Alton Sells 14,435 Shares of Stock” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/22/gilead-sciences-inc-gild-evp-gregg-h-alton-sells-14435-shares-of-stock.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.